At a Glance
- CD34+ cell therapy company with an advanced clinical pipeline with 2 programs with “breakthrough” designation and 1 targeting COVID-19 induced lung repair
- Proprietary field-leading technology in multi-billion dollar global indications backed by a strong IP portfolio
- Multiple potential value creating events in the next 12-18 months based on development milestones across the pipeline (timing subject to COVID-19 pandemic influence)
- Seasoned management team with noteworthy domain expertise along with big pharma and emerging biotech experience
- Strong balance sheet; ~$34 million in cash and cash equivalents (April 30, 2020) with no debt and cash runway projected to fund operations into 2H 2021
Maximum 30 minute delay for quote.